Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northwest Biotherapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (47)	8/22/2006 4:53:52 AM
From: zeta1961	Respond to of 760

Many, many thanks John, for digging up and posting these trials..the last author, Loeffler, is a Massachusetts General Hospital uber neuro-onc radiation doc..one of the best in the world..imo, whatever he says is gospel..I used to hand deliver Jeff's MRI's and PET's to him..and also funny as any comedian..we asked him once why it's taking so long for Jeff's hair on his scalp to come back..his response: "Your follicles are pissed off, what do you expect?"...he also was of the few who continued to be in touch AFTER he died.. Elisabeth

To: John McCarthy who wrote (47)	8/22/2006 5:06:32 AM
From: zeta1961	Respond to of 760

Detailed paper on NWBT's P1 glioblastoma vaccine..very interesting for those more inclined toward immunotherapeutic route.. Quite importantly, to evaluate P2 trial methodology, although they enrolled patients 'as they came,' those needing steroids like dexamethasone were excluded..this criterium naturally selects for patients with tumors in less harmful parts of the brain and for those who most of the tumor was excised..they admitted this in this piece..

To: John McCarthy who wrote (47)	8/22/2006 5:11:40 AM
From: zeta1961	Respond to of 760

Detailed paper on NWBT's P1 glioblastoma vaccine..very interesting for those more inclined toward immunotherapeutic route.. clincancerres.aacrjournals.org Quite importantly, to set up P2 trial methodology, although they enrolled patients 'as they came,' those needing steroids like dexamethasone were excluded..this criterium naturally selects for patients with tumors in less harmful parts of the brain and for those whose tumor was excisable even if not completely..they admitted these limitations in this piece..acknowledging, they compared against historicals of patients with the best prognostic factors(age, tumor size and location and neuro deficits) and still the TTP and OS were better than expected.. I wish Miljenko would come over here and break my and their analysis apart.. Elisabeth